Johnson & Johnson (NYSE:JNJ) Shares Acquired by Impact Capital Partners LLC

Impact Capital Partners LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 11.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 23,573 shares of the company’s stock after buying an additional 2,380 shares during the quarter. Johnson & Johnson accounts for 1.4% of Impact Capital Partners LLC’s holdings, making the stock its 13th largest position. Impact Capital Partners LLC’s holdings in Johnson & Johnson were worth $3,909,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $32,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.9%

Shares of NYSE:JNJ opened at $155.02 on Friday. The firm has a fifty day moving average of $153.59 and a two-hundred day moving average of $153.68. The firm has a market capitalization of $372.99 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.